Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
40 hedge funds and large institutions have $101M invested in Eiger BioPharmaceuticals, Inc. in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
86% more capital invested
Capital invested by funds: $54.4M → $101M (+$46.8M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
21% more funds holding
Funds holding: 33 → 40 (+7)
10% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$7.2M |
| 2 |
AC
Armistice Capital
New York
|
+$4.57M |
| 3 |
DM
Deerfield Management
New York
|
+$3.57M |
| 4 |
HCM
Highbridge Capital Management
New York
|
+$2.2M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$1.52M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$960K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$518K |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$341K |
| 5 |
Millennium Management
New York
|
-$152K |
EIGR Hedge Fund Activity: Q4 2017 in Review
40 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q4 2017, worth a combined $101M — up 86% from $54.4M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EIGR positions and 5 closed out — a net gain of 7 holders — while 9 added to existing stakes and 10 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $7.2M. The largest seller was Boxer Capital, exiting entirely with an estimated $1.52M sold.
- 40 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q4 2017, up from 33 in Q3 2017.
- Funds reported $101M of Eiger BioPharmaceuticals, Inc. stock for Q4 2017, up 86% quarter-over-quarter.
- 12 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q4 2017 and 5 closed out, a net change of +7 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q4 2017 was Jennison Associates, an estimated $7.2M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q4 2017 was Boxer Capital, an estimated $1.52M sold.
Based on aggregated 13F filings for Q4 2017.